MagXite

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive disease that damages the nerve cells controlling muscles. A major diagnostic challenge is to objectively identify damage to the upper motor neurons in the brain. Standard methods often fail to do this, leading to an average diagnostic delay of 8 months.

A promising approach for developing biomarkers of motor cortex damage in ALS is the assessment of short-interval intracortical inhibition (SICI) using paired-pulse transcranial magnetic stimulation (TMS) and the threshold tracking technique. MagXite is a unique solution that automates this assessment.

Early and Accurate Diagnosis

The method can detect the disease at early stages, even with minimal symptoms. It accelerates diagnosis by an average of 8 months1 compared to the El Escorial criteria, the recognized gold standard for ALS. Method accuracy: 74% sensitivity and 81% specificity for distinguishing ALS from other disorders2.

Objective Evaluation of Treatment

MagXite allows clinicians to monitor how drugs (e.g., riluzole) affect the nervous system. This is critical for tailoring therapy and conducting clinical trials for new medications3.

Simple, Fast and Comfortable

The entire procedure takes about 30–40 minutes and is comfortable for the patient. The fully automated algorithm allows for easy integration into clinical practice. Physicians do not require highly specialized knowledge to perform the test. Who is MagXite for? Neurology departments and clinics: for precise differential diagnosis of ALS and monitoring disease progression. Research centers: as an objective biomarker for trials of new ALS therapeutics.

A Technology You Can Trust

MagXite implements the threshold tracking TMS technology pioneered by leading global experts Professor Matthew Kiernan and Professor Steve Vucic. Its utility has been independently confirmed by renowned Russian scientists from the Research Center of Neurology. The method has become an international standard in ALS diagnosis and is included in international guidelines for diagnostic TMS.

Don't lose precious time. Help your patients to get a precise diagnosis using MagXite.

You can find more information here.

1. Vucic S, Cheah BC, Yiannikas C, Kiernan MC. Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol. 2011 Sep;122(9):1860-6. doi: 10.1016/j.clinph.2010.12.062. Epub 2011 Mar 5. PMID: 21382747.

2. Menon P, Geevasinga N, Yiannikas C, Howells J, Kiernan MC, Vucic S. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol. 2015 May;14(5):478-84. doi: 10.1016/S1474-4422(15)00014-9. Epub 2015 Apr 3. Erratum in: Lancet Neurol. 2015 Jun;14(6):566. PMID: 25843898.

3. Vucic S, Lin CS, Cheah BC, Murray J, Menon P, Krishnan AV, Kiernan MC. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain. 2013 May;136(Pt 5):1361-70. doi: 10.1093/brain/awt085. PMID: 23616585.